Phaseline

Companies › ImCheck Therapeutics, an Ipsen company

ImCheck Therapeutics, an Ipsen company: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ICT01
humanized anti-BTN3A monoclonal antibody
BTN3APhase 1Solid Tumor, AdultOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04243499ICT01Phase 1Solid Tumor, AdultOncologyOct 2027

Targets

BTN3A (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.